COVID-19 has brought disease and mortality at levels not seen from a respiratory virus for over 100 years. Immune responses to this virus, which can infect several different tissues, are poorly understood, including the role of antibodies in resolving the infection. In March 2020, we reoriented our lab to develop Enzyme-Linked ImmunoSorbent Assays (ELISA) for human antibody isotypes IgM, IgG and IgA produced in response to the SARS-CoV-2 spike protein. To date we have analyzed samples from 114 patients, including both PCR positive and PCR negative individuals.
Rohan Shanbhag will be discussing how Achu Health has developed an application based on a machine learning algorithm that uses data collected from a smartwatch to predict illness in individuals using the application. Achu Health aims to assess the scientific rigour of its application to ensure that the evaluation with evaluation by Health Science professionals.
About Achu Health: